BofA raised the firm's price target on Eli Lilly to $1,251 from $1,133 and keeps a Buy rating on the shares. The firm expects Lilly's overall revenue and profit growth to be keyed by doubling of GLP-1 U.S. market sales by 2033, the analyst tells investors.
